ImmuPharma (IMM) Rating Reiterated by Northland Securities

ImmuPharma (LON:IMM)‘s stock had its “buy” rating reaffirmed by investment analysts at Northland Securities in a report released on Thursday. They presently have a GBX 181 ($2.45) price target on the stock. Northland Securities’ target price would indicate a potential upside of 7.42% from the stock’s current price.

IMM has been the topic of several other research reports. FinnCap assumed coverage on shares of ImmuPharma in a report on Tuesday, December 12th. They issued a “buy” rating and a GBX 237 ($3.21) price target on the stock. Northland Capital Partners reiterated a “buy” rating and issued a GBX 181 ($2.45) price target on shares of ImmuPharma in a report on Thursday, September 21st.

ImmuPharma (LON:IMM) traded up GBX 13.50 ($0.18) during trading hours on Thursday, reaching GBX 168.50 ($2.29). 1,716,582 shares of the company traded hands, compared to its average volume of 468,352. The company has a market capitalization of $218.49 and a PE ratio of -4,212.50. ImmuPharma has a twelve month low of GBX 44 ($0.60) and a twelve month high of GBX 193.74 ($2.63).

ILLEGAL ACTIVITY WARNING: “ImmuPharma (IMM) Rating Reiterated by Northland Securities” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at

About ImmuPharma

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with's FREE daily email newsletter.

Leave a Reply